Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy.
Hematology Division, University Hospital Policlinico "Paolo Giaccone,", Palermo, Italy.
Chemotherapy. 2024;69(1):35-39. doi: 10.1159/000533235. Epub 2023 Aug 25.
Castleman disease is non-clonal lymphoproliferative disorders defined by hypertrophy of lymph nodes. The multicentric form (MCD), in which multiple lymph node stations are involved, is not associated with HHV8 infection, but considered idiopathic, although IL-6 appears to play a central role in its pathogenesis. Here, we report the case of a patient who presented with mixed autoimmune hemolytic anemia (AIHA) and adenopathy that was very challenging to diagnose due to very low values of hemoglobin and refractoriness of obtaining any improvement of AIHA with standard first and second lines of therapy (steroids, rituximab, immunoglobulin, erythropoietin, and cyclosporine). When we safely proceeded to lymph node biopsy, a diagnosis of MCD was established. This permitted the treatment with siltuximab, an anti-IL-6 monoclonal antibody. After only 1 week, hemoglobin raised and he was discharged. After 1 year, he was still in remission. This case underlines the challenges in diagnosis of MCD, and the first case of response to siltuximab after the failure of rituximab to relieve mixed AIHA.
卡斯尔曼病是一种非克隆性淋巴组织增生性疾病,其特征为淋巴结肿大。多中心型(MCD)不伴有 HHV8 感染,涉及多个淋巴结部位,被认为是特发性的,尽管白细胞介素 6(IL-6)似乎在其发病机制中起核心作用。在这里,我们报告了一例患者,其表现为混合自身免疫性溶血性贫血(AIHA)和腺病,由于血红蛋白值非常低,以及标准的一线和二线治疗(类固醇、利妥昔单抗、免疫球蛋白、促红细胞生成素和环孢素)对 AIHA 的改善效果不佳,导致诊断极具挑战性。当我们安全地进行淋巴结活检时,诊断为 MCD。这允许使用西妥昔单抗(一种抗白细胞介素 6 单克隆抗体)进行治疗。仅仅 1 周后,血红蛋白升高,患者出院。1 年后,他仍处于缓解期。该病例强调了 MCD 诊断的挑战,以及在利妥昔单抗未能缓解混合 AIHA 后,首例对西妥昔单抗有反应的病例。